Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Radotinib is a second‐generation BCR‐ABL1 tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia in chronic phase (CP‐CML). Here, using the data from a Phase 3 study conducted in patients with newly diagnosed CP‐CML, the dose–efficacy as well as dose–safety relationship ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Noh, Hayeon, Jung, Su Young, Kwak, Jae‐Yong, Kim, Sung‐Hyun, Oh, Suk Joong, Zang, Dae Young, Lee, Suhyun, Park, Hye Lin, Jo, Dae Jin, Shin, Jae Soo, Do, Young Rok, Kim, Dong‐Wook, Lee, Jangik I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943471/
https://www.ncbi.nlm.nih.gov/pubmed/29577681
http://dx.doi.org/10.1002/cam4.1436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943471/
https://www.ncbi.nlm.nih.gov/pubmed/29577681
http://dx.doi.org/10.1002/cam4.1436

Ejemplares similares